|Position||Trades||Duration||Win rate||Win/loss||Avg win||Avg loss||Return|
|Position||Trades||Duration||Win Rate||Win/Loss||Avg Win||Avg Loss||Return|
Ra Pharmaceuticals Inc (RARX)
EASE OF MOVEMENT
Trading: SELL @ $46.58
Signal Strength: MEDIUM
Volatility indicators highlight potential moves of a stock which can either move sharply in the updwards or downwards direction. This indicator allows stocks to be compared on a level playing field to highlight high and low volatility. Normally, falling markets are more likely to be volatile than a rising markets due to the emotion that gets tied to trading. Use volatility indicators in conjunction with other indicators to reduce exposure to false moves.
Ra Pharmaceuticals Inc (NASDAQ:RARX) current price have moved downwards on low volume. Currently, the EOM is -22.166.
The Ease of Movement (EOM) is a technical momentum indicator that is used to illustrate the relationship between the rate of an assets price change and its volume. This indicator attempts to identify the amount of volume required to move prices. Generally a value greater than zero is an indication that the stock is being accumulated (bought) and negative values are used to signal increased selling pressure. A high positive value appears when prices move upward on low volume. Strong negative numbers indicate that price is moving downward on low volume.
Calculation: Ease of Movement (EOM):
1) Distance Moved = ((H + L)/2 - (Prior H + Prior L)/2);
2) Box Ratio = ((V/100 000 000)/(H - L));
3) 1-Period EMV = ((H + L)/2 - (Prior H + Prior L)/2) / ((V/100 000 000)/(H - L));
4) 14-Period Ease of Movement = 14-Period simple moving average of 1-period EMV
PROFILE: Ra Pharmaceuticals Inc (RARX)
Stock Exchange: NASDAQ
Company: Ra Pharmaceuticals Inc
Ticker Codes: | RARX | NASDAQ:RARX |
Ra Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of diseases caused by excessive or uncontrolled activation of the complement system in the United States. The company's peptide chemistry platform enables the production of synthetic macrocyclic peptides that combine the diversity and specificity of antibodies with the pharmacological properties of small molecules. Its lead product candidate is RA101495, an injection into the tissue under the skin that has completed Phase II clinical trial for the treatment of paroxysmal nocturnal hemoglobinuria (PNH); and is in Phase II clinical trial for treating patients with generalized myasthenia gravis (gMG), as well as in Phase 1b clinical trial for treating atypical hemolytic uremic syndrome (aHUS) and lupus nephritis (LN). The company's preclinical testing products include Factor D inhibition for orphan renal and dense deposit diseases, and C3 glomerulonephritis; Oral C5 inhibitor for PNH, gMG, aHUS, LN, and central nervous system (CNS) diseases; and other complement inhibitors for autoimmune/CNS diseases. It has multi-target collaboration and license agreement with Merck & Co., Inc. Ra Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Cambridge, Massachusetts.
|INO Inovio Pharma||4.36||9.3||34,675,337||1,782.41||BULLISH|
|VIVO Meridian Bioscience||8.16||9.2||1,886,706||1,402.34||BULLISH|
|BCRX BioCryst Pharmaceuticals||2.74||8.3||11,180,169||980.55||BULLISH|
|STAA Staar Surgical||31.05||8||1,662,302||3,983.93||BULLISH|
|CRIS Curis Inc||1.23||7||256,944||3.45||BULLISH|
|KPTI Karyopharm Therapeutics||15.38||7||1,860,063||887.68||BULLISH|
|PME Pingtan Marine||1.26||5||12,660||247.45||BULLISH|
|HSII Heidrick & Struggles||22.2||3.8||207,252||5.76||BULLISH|
|SYRS Syros Pharmaceuticals||6.65||3.3||129,382||17.76||BULLISH|